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 Dear Editor,
 Medication-overuse headache (MOH) is a condition in 
which the headache treatment becomes the cause. A person 
with headache starts taking frequent pain medication that 
will lead to headache worsening and a cycle of increasing 
medication use and increased pain.1 The possibility of 
medication overuse as a headache cause is frequently 
ignored by patients and health professionals,1 making it a 
public health problem.2 
MOH prevalence is estimated in 1% - 2%,1,2 but it is 
present in up to 10% of migraineurs.3 MOH is associated 
with lower quality of life2 and it must be recognized to be 
effectively treated.2 To our knowledge, there is no study 
addressing this problem in Portugal.
Considering a prevalence of 10%3 (with a precision of 
5% and for a confidence level of 95%) a sample size of 
139 would be necessary to assess MOH prevalence. We 
included 146 consecutive patients with a migraine diagnosis 
according to the International Classification of Headache 
Disorders-III beta, observed for the first time in a Headache 
Outpatient Clinic. Demographical, social and headache-
related data were collected. Anxiety and depressive 
symptoms were evaluated using the Hospital Anxiety and 
Depression scale (HADS), disability was assessed using 
the Headache-Attributed Lost Time questionnaire (HALT). 
MOH was diagnosed in 11/146 migraineurs (7.53%, 
95% CI: 4.26 - 12.98). The average number of analgesics 
used per patient was 1.72, with six patients (54.5%) using 
only one drug. Non-steroid anti-inflammatory drugs were 
the most commonly used (6/11), followed by paracetamol 
(5), metamizole (4), triptans (3) and acetylsalicic acid (1). 
Migraineurs with a MOH diagnosis were older and reported 
higher disability than those without MOH. MOH was also 
associated with chronic migraine. Full comparisons can be 
found in Table 1.
Although our results could be biased by due to our 
hospital based-sample, we provide the first estimate of MOH 
prevalence in Portuguese migraineurs. In line with what was 
previously described, we found that MOH is more common 
in the forties4 and associated with chronic migraine.1 This 
information could help clinicians identify headache patients 
with higher risk of MOH – a condition associated with higher 
headache-related disability.1 
Primary care physicians stand in a privileged position to 
identify and prevent the development of MOH in headache 
patients. Simultaneously, neurologists and primary care 
physicians should work together to understand the local and 
national dimension of this problem and to develop effective 
public health approaches to minimize this problem. This 
could include the development of online education tools.5 
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n = 135 p-value
Age, years 45.0 (6.0) 34.0 (17.0) 0.007
Age at onset of primary headache, years 28.0 (21.0) 16.5 (8.0) 0.024
Duration of disease, years 15.0 (25.0) 14.5 (15.0) 0.829
Female gender, n (%) 11 (100.0%) 121 (89.6%) 0.601
BMI, kg/m2 25.0 (8.0) 23.5 (5.0) 0.623
Migraine type 0.029
  Episodic 8 (72.7%) 128 (94.8%)
  Chronic 3 (27.3%) 7 (5.2%)
Pain intensity, VAS 9.0 (2.0) 8.0 (2.0) 0.101
HALT 47.0 (112.0) 16.0 (24.0) 0.022
HADS-A 7.0 (4.0) 8.5 (6.0) 0.603
HADS-D 3.0 (4.0) 4.5 (5.0) 0.376
Comparison of migraineurs with medication overuse headache (migraine + MOH) and without (migraine – MOH). Data expressed as median and interquartile range for continuous 
variables, and number and percentage for categorical ones. Comparisons were performed using the Fisher’s exact test for categorical variables and Mann-Whitney’s U test for 
continuous. Significance level was set at 0.05. 
BMI: body mass index; VAS: visual analogue scale; HALT: headache attributed lost-time; HADS: hospital anxiety and depression scale; A: anxiety; D: depression
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Letter to the Editor,
 We read with interest the article by Alves et al about a 
55-years-old female with maternally-inherited diabetes and 
deafness (MIDD) due to the mtDNA-variant m.3243A>G.1 
In the index patient’s family five other members were 
also clinically affected (II/5, II/1, II/2, II/3, I/1).1 In addition 
to deafness and diabetes some family members also 
presented with hypertrophy cardiomyopathy (II/3, II/4, II/5), 
conduction-block (II/2, II/4), myopathy (II/4), depression 
(II/4), cognitive impairment (II/1, II/4, II/5), basal ganglia 
calcification (II/5), cerebellar atrophy (II/5), macular 
dystrophy (II/1, II/4, II/5), proteinuria (II/4, II/5), and muscle 
weakness (II/4).1 We have the following comments and 
concerns. 
 Phenotypic features in MIDD-patients other than deaf-
ness and diabetes are not uncommon.2 MIDD not only man-
ifests as insulin-deficient diabetes and hearing loss but also 
as epilepsy, cerebellar ataxia, cognitive impairment, basal 
ganglia calcification, Parkinson syndrome, cerebral atrophy, 
stroke, maculopathy, retinopathy, cataract, hyporeninemic 
hypoaldosteronism, hypothyroidism, short stature, hypo-
parathyroidism, Addison-disease, dilated cardiomyopathy, 
WPW-syndrome, intestinal pseudoobstruction, pancreati-
tis, non-diabetic renal insufficiency, glomerulosclerosis, or 
myopathy.2 Thus, MIDD is definitively a multisystem mito-
chondrial disorder (MIMODS) depending on the stage of the 
disease. At onset or during the first years only the pancreas 
and ears may be affected but with progression of the dis-
ease MIMODS may develop. 
 Since MIDs occasionally manifest with unilateral or 
bilateral basal ganglia calcification and since II/5 also 
presented with basal ganglia calcification, it would be 
interesting to know if T2-hypointensitiy in figure 2 of the 
case report was attributable to basal ganglia calcification 
or bleeding? Was there any evidence of calcification of the 
basal ganglia on cerebral CT? Did CT scans in other family 
members also show basal ganglia calcification?
 Since clinical manifestations of the m.3243A>G 
mutation may strongly depend on the mutation load, it 
should be explained why cases II/2, II/3, and II/5, who had 
lower heteroplasmy rates than the clinically unaffected case 
III/1, nonetheless manifested clinically. Were heteroplasmy 
rates also determined in tissues other than lymphocytes? 
Did heteroplasmy rates vary between different tissues? 
 We do not agree with the statement that there is no 
curative therapy for MIDs.1 Patients with MIDs not only 
profit from symptomatic measures and supplementary 
therapy but in a few cases also causal measures can be 
highly effective, such as in MNGIE or primary coenzyme-Q-
deficiency.3 
 Overall, this interesting case study may profit from 
determination of heteroplasmy rates in tissues other than 
lymphocytes, from prospective investigations of subclinical 
or mild clinical manifestations of the mutation, and from 
symptomatic or supplementary therapeutic measures. 
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